Vantictumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | Frizzled receptor |
| Clinical data | |
| Routes of administration | IV |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6322H9722N1674O1988S46 |
| Molar mass | 142461.81 g·mol−1 |
Vantictumab /vænˈtɪktʊmæb/ is a human IgG2 monoclonal antibody designed for the treatment of cancer.[1]
This drug was developed by OncoMed Pharmaceuticals Inc. in partnership with Bayer.[2] OncoMed was awarded a patent in 2016, which is set to expire in 2029.[3] In April 2017, Bayer terminated its option to license vantictumab.[4]
It inhibits wnt signalling by targeting the frizzled receptors on cancer cells.[5]
Phase I trials have been completed for
non-small cell lung cancer, and breast cancer. In 2016 results were reported from a phase 1b clinical trial for triple-negative breast cancer[5][6] and in 2020 for pancreatic cancer.[7]
References
- ^ "Statement on a nonproprietary name adopted by the USAN Council" (PDF). AMA. 28 Nov 2012. N12/155.(registration required)
- ^ "OncoMed Pre-Announces 2014 Year-End Cash Balance and Provides 2015 Guidance" (Press release). 12 January 2015.
- ^ "Annual Report on Form 10-K". OncoMed Pharmaceuticals, Inc. Archived from the original on 13 January 2017.
- ^ "BRIEF-Oncomed Pharmaceuticals announces Bayer terminates its option to license vantictumab or ipafricept". Reuters. 10 April 2017.
- ^ a b "Finally, targeted therapies for triple-negative breast cancer". Medical Xpress. June 2016.
- PMID 32803633.
- PMID 31338636.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |